The pituitary lactotroph, a well established target for estrogens, expresses estrogen receptor-␣ (ER␣) and -␤ (ER␤). A truncated isoform of ER␣, named TERP, is expressed in the pituitary, but not in the uterus. In this study we used the somatolactotroph cell line, GH 3 cells, to examine 1) the expression of ER␣, TERP, or ER␤ and their regulation by estradiol; 2) the presence of receptor proteins; and 3) the effects of overexpressing ER␤ or TERP on estrogen induction of the PRL gene and activation of the estrogen response element (ERE).
throughout the pituitary; its specificity was demonstrated by preabsorption with the synthetic peptide. The antibody detected a 58-to 60-kDa protein by Western blotting of ovarian, pituitary, and GH 3 cell extracts. Cotransfection of ER␤ and reporter genes (PRL promoter/ luciferase or ERE/luciferase) into GH 3 cells resulted in a dose-dependent increase in estrogen-induced PRL gene expression, with a lesser activation of the ERE. A 20-kDa TERP protein was undetectable in untreated GH 3 cells and was weakly induced by estradiol. Overexpression of TERP had no effect on estrogen induction of either PRL or ERE.
We conclude that 1) both ER␤ and TERP messenger RNAs in GH 3 cells are increased by estradiol in a dose-and time-dependent manner, whereas ER␣ is not altered; 2) a 58-kDa ER␤ protein is expressed in both the pituitary and GH 3 cells; and 3) overexpression of ER␤ increases estrogen-induced PRL gene expression. (Endocrinology 140: [2651] [2652] [2653] [2654] [2655] [2656] [2657] [2658] 1999) T HE PITUITARY lactotroph is a well established target cell of estrogens. Estrogen increases PRL gene expression, synthesis, storage, and release as well as lactotroph proliferation (1) (2) (3) (4) . Other estrogen-responsive genes in the lactotroph include c-fos (5), galanin (6) , and vascular endothelial growth factor (7) , which are up-regulated by estrogen, and transforming growth factor-␤, which is down-regulated (8) . The actions of estrogens could be mediated by three estrogen receptors, ER␣, its truncated isoform, and ER␤.
ER␤, first identified in the rat prostate and ovary (9) , shares several similarities with ER␣. Both receptors have a high binding affinity for estrogen and activate the same estrogen response element (ERE) (10) , but differ in their trans-activation domains, suggesting distinct roles in gene activation. At the messenger RNA (mRNA) level, ER␤ has been detected in many tissues, including rat (11, 12) and human (13) , but not mouse (14) , pituitaries. Using a combined immunocytochemistry/in situ hybridization approach, we detected ER␤ expression in most pituitary cell types, including 30% of the lactotrophs (12) . However, ER␤ has not been well demonstrated at the protein level due to the limited availability of specific antibodies. In addition, the specific actions of this receptor within the pituitary gland have not been delineated.
The truncated estrogen receptor product (TERP), discovered by Shupnik et al. (15, 16) , lacks exons 1-4 of ER␣ but contains most of the hormone-binding domain and the second trans-activation domain. Given these structural properties, TERP may act either as a dominant negative regulator or as an enhancer of estrogenic action. TERP is expressed in the pituitary, but not in the uterus, and its mRNA levels increase in response to estrogen (12, 16) . Pituitary TERP gene expression is altered during the estrous cycle, with the highest mRNA levels seen on the morning of proestrus (17) . Although not all of the pituitary cell types that express TERP have been identified, cell separation experiments revealed that the lactotroph-enriched fraction had the highest amount of TERP mRNA (18) . GH 3 cells, a rat somatolactotroph cell line, are widely used as an in vitro model for the lactotrophs. When these cells are maintained under low estrogen conditions, exogenous estrogens increase PRL synthesis and release (19 -21) and exert a biphasic effect on cell proliferation (1) . Binding studies revealed the presence of ERs in GH 3 cells (22) , but neither the identity of the receptor nor its regulation by estrogen have been examined.
In this study, we used GH 3 cells as an in vitro model for investigating several aspects of the ERs in lactotrophs. The objectives were to 1) examine the expression of ER␣, TERP, and ER␤ and compare their regulation by estradiol; 2) generate an ER␤ antibody to characterize ER␤ protein expression in the pituitary and GH 3 cells; and 3) determine the effects of ER␤ or TERP overexpression on the PRL gene and ERE activation.
Materials and Methods

Constructs and ER␣ antiserum
The TERP1 and ER␤ expression vectors were provided by Drs. K. Friend (University of Texas, Houston, TX) and R. Lupu (University of California, Berkeley, CA), respectively. The 1.9-kb PRL promoter/luciferase reporter gene (PRL/luc) was obtained from Dr. R. Maurer (Oregon Health Sciences University, Portland, OR), and a triple vitellogenin ERE/luciferase construct (ERE/luc) was obtained from Dr. C. Jordan (Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, IL). The ER␣ antiserum (directed against a synthetic peptide at the extreme C-terminus of ER␣) was provided by Dr. M. Shupnik (University of Virginia, Charlottesvile, VA).
Animals
All animal studies were performed under an institutionally approved protocol according to the USPHS Guide for the Care and Use of Laboratory Animals. Intact and ovariectomized Fischer 344 rats (7-8 weeks old) were obtained from Zivic-Miller (Zelienpole, PA) and were maintained under standard conditions.
GH 3 cell culture
GH 3 cells were maintained in Ham's F-10 medium supplemented with 15% heat-inactivated gelding serum (Central Biomedia, Lenexa, KS) that has undetectable estrogen levels. Two or 3 days before an experiment, cells were plated in serum-free medium composed of DMEM and Ham's F-10 (50:50) supplemented with ITSϩ premix (Collaborative Research, Inc., Bedford, MA) and penicillin/streptomycin. For RT-PCR, 500,000 cells were plated in 12-well plates coated with protamine (Sigma Chemical Co., St. Louis, MO) and Nu-Serum (Collaborative Research, Inc.) as previously described (23) . For transfection experiments, 75,000 cells were plated on similarly coated 24-well plates.
RT-PCR for ER␣, TERP, and ER␤
Total RNA was isolated from GH 3 cells using Tri-Reagent (Molecular Research Center, Inc., Cincinnati, OH), and 5 g were reverse transcribed using random hexamers and Superscript II reverse transcriptase (Life Technologies, Gaithersburg, MD) as previously described (12) . Primer sequences and expected product sizes were: 1) ER␣ sense primer, 5Ј-GGTCCAATTCTGACAATCGAGC-3Ј; ER␣ antisense primer, 5Ј-TT-TCGTATCCCGCCTTTCATC-3Ј (with an expected size of 304 bp); 2) TERP sense primer, 5Ј-GCTTGTTGAACAGCGACCAG-3Ј; TERP antisense primer, 5Ј-CTTGTCCAGGACTCGGTG-3Ј (with an expected size of 366 bp for TERP1); and 3) ER␤ sense primer, 5Ј-AACACTTGC-GAAGTCGGCAG-3Ј; ER␤ antisense primer, 5Ј-AACCTCAAAA-GAGTCCTTGGTGTG-3Ј (with an expected size of 327 bp). Each reaction also contained primers for ribosomal protein L19 (RPL19), which served as an internal control: sense primer, 5Ј-AGTAGTCTTAGGCTACA-GAAG-3Ј; and antisense primer, 5Ј-TTCCTTGGTCTTAGACCTGCG-3Ј (with an expected size of 500 bp).
Optimal PCR conditions for each receptor were determined by varying the cycle number, RNA concentration, and annealing temperature as previously described (12) . PCR products were separated on a 1% agarose gel stained with ethidium bromide, photographed, and analyzed by scanning densitometry (Scion Image Software, Frederick, MD).
ER␤ antibody production
An 18-amino acid peptide from the N-terminus of ER␤ (amino acids 48 -65) was made by solid phase synthesis on a multiple antigenic peptide backbone (Protein and Carbohydrate Structure Facilities, University of Michigan, Ann Arbor, MI). New Zealand rabbits (Harlan Bioproducts, Indianapolis, IN) were used for a standard 90-day protocol. Enzyme-linked immunosorbent assays were performed to determine antibody titer.
Immunohistochemistry for ER␤
Immunohistochemistry was performed as previously described (5). Briefly, pituitary or ovary cryosections (10 m) were mounted on silanecoated slides and fixed in 4% paraformaldehyde for 20 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in 70% methanol for 30 min at 4 C, and the sections were permeabilized with 0.1% Triton-X for 10 min. The slides were incubated with ER␤ antiserum (1:1000) overnight at 4 C, and staining was performed using biotinylated secondary antibodies and avidin-biotin-peroxidase complex (ABC kit, Vector Laboratories, Inc., Burlingame, CA). Brown color was visualized after 2-min incubation with diaminobenzidine. Some sections were counterstained with hematoxylin. For controls, 50 l of the antiserum were preabsorbed with 100 g of the synthetic peptide by overnight incubation at 4 C. Both antibody and synthetic peptide are available from Upstate Biotechnology (Lake Placid, NY).
Western blotting for ER␣, TERP, and ER␤
Pituitaries and ovaries were removed and immediately frozen. GH 3 or COS-1 cells were pelleted and frozen. Samples were homogenized in lysis buffer [50 mm Tris-HCl (pH 7.5), 150 mm NaCl, and 5 mm EDTA] containing the following protease inhibitors: 0.25% sodium deoxycholate, 1 mm phenylmethylsulfonylfluoride, 1 mm NaF, and 1 g/ml each of aprotinin, leupeptin, and pepstatin. Homogenates were centrifuged at 13,000 ϫ g, and the supernatants were subjected to protein determination with a BCA protein assay (Pierce Chemical Co., Rockford, IL). Recombinant human ER␤ (100 ng) from PanVera (Madison, WI) served as a positive control. Proteins (30 g) were electrophoresed on a 10% or 12% polyacrylamide gel, electrotransferred to nitrocellulose membranes (Schleicher & Schuell, Inc., Keene, NH), and stained with Ponceau S (Sigma Chemical Co.) to visualize the transfer. The blots were blocked with 2% nonfat milk and incubated overnight at 4 C with either ER␤ (1:2000) or ER␣ (1:7500) antisera. An enhanced chemiluminescence kit (Amersham, Arlington Heights, IL) was used to visualize the products.
Subcloning of TERPs
TERP expression vectors using alternative start sites (see Fig. 6 ) were PCR amplified from anterior pituitary complementary DNAs (cDNAs) using the following primers: Met 401 sense primer, 5Ј-TTGAATTCGAT-TGGTCTGGTCTG-3Ј; Met 426 sense primer, 5Ј-TTGAATTCGGACAG-GAATCAAGG-3Ј; and the same antisense primer for both, 5Ј-TTTCTA-GAGCTTCTCAGATGGTGTT-3Ј. The products were ligated into a pTarget expression vector (Promega Corp., Madison, WI) and confirmed by sequence analysis.
Cell transfection
GH 3 cells in each well were transiently transfected using a solution containing 1) 250 ng PRL/luc or 250 ng ERE/luc reporter genes, 2) 25 ng ␤-galactosidase, 3) increasing amounts (0.5-25 ng) of ER␤ (in pcDNA) or TERP (in pTarget) expression vectors, and 4) 2 g lipofectamine (Life Technologies). Control cells were cotransfected with the respective reporter genes, ␤-galactosidase, and comparable amounts of empty expression vectors. Cells were incubated with the transfection mixture in OPTI-MEM (Life Technologies, Inc.) for 6 h. After the addition of medium containing gelding serum for 24 h, the cells were incubated for 18 h with 1 nm estradiol or vehicle in serum-free medium.
COS-1 cells, maintained in DMEM and 10% FBS, were trypsinized, and 1 ϫ 10 6 cells were plated on 100-mm plates. For transfection, 5 g of each of the different TERP expression vectors and 35 g lipofectamine were incubated for 6 h, followed by the addition of medium containing gelding serum for 24 h.
Reporter gene assays
GH 3 cells were washed in PBS and lysed in 100 l lysis buffer (Promega Corp.), and duplicate 20-l aliquots were transferred to separate black plates (Packard Instrument Co., Meriden, CT). For luciferase determination, 80 l luciferin substrate (Promega Corp.) were added. For ␤-galactosidase determination, 80 l Galacton-Plus substrate (Tropix, Bedford, MA) were added and incubated for 25 min at room temper-ature, and then 200 l of accelerator II (Tropix) were added immediately before counting. Luminometry was quantitated by using a Packard TopCount.
Data analysis
For RT-PCR, the density ratio of receptor/RPL19 bands was calculated and expressed as a percentage of the control values (no estrogen), with each data point representing four to six determinations. For transfections, the ratio of reporter gene/␤-galacosidase activity was determined and expressed as a percentage of control values (no estrogen). Triplicate transfections were performed four to six times. All values are expressed as the mean Ϯ sem. Statistical significance was determined using ANOVA followed by Dunnett's post-hoc test.
Results
Regulation of ER mRNA levels by estradiol
The effects of incubating GH 3 cells for 24 h with increasing doses of estradiol on ER␣, TERP, and ER␤ mRNA levels are shown in Fig. 1, left panel. As determined by quantitative RT-PCR, the expression of TERP increased in a dose-dependent manner, reaching levels 4-and 5-fold above control values in response to 1 and 10 nm estradiol, respectively (P Ͻ 0.05). ER␤ mRNA levels increased 3-fold by 1 nm estradiol (P Ͻ 0.05) without a further rise with the 10-nm dose. In contrast, ER␣ mRNA levels were unaffected by estradiol at all doses tested. A dose of 1 nm estradiol was selected for the time-course experiments. As shown in Fig. 1 , right panel, estrogen treatment increased both TERP and ER␤ mRNA levels in a time-dependent manner, whereas ER␣ levels were unchanged. Interestingly, TERP mRNA levels rose in a biphasic manner, reaching 6-fold above control values at 3 h (P Ͻ 0.05), decreasing to 3-fold by 6 h (P Ͻ 0.05), and rising again at 24 h (P Ͻ 0.05). Compared with TERP, the rise in ER␤ mRNA was delayed, reaching its highest level of 3-fold above the control values (P Ͻ 0.05) after 24 h.
Nuclear staining in the ovary and pituitary with the ER␤ antiserum
Given the expression of ER␤ in GH 3 cells and its upregulation by estrogen, we wanted to determine whether these cells produce the ER␤ protein. Due to the paucity of commercially available antibodies, we generated our own ER␤ antibody. For that, we made an 18-amino acid synthetic peptide with 100% homology in human, rat, and mouse ER␤ genes. To characterize the antiserum, we used the rat ovary. Figure 2 , upper left panel, shows a mature Graffian follicle positively stained for ER␤ protein, with a weaker and more diffuse staining seen in the ovarian stroma as well as near blood vessels. The two insets demonstrate strong brown nuclear staining in the majority of granulosa cells surrounding the ovum and the antral cavity. The marked attenuation of nuclear staining by ER␤ antisera preabsorbed with the synthetic peptide (upper right panel) establishes the specificity of the antibody. 
ER␤ protein is expressed in both the pituitary and GH 3 cells
Western blotting was performed on extracts of ovary, pituitary, and GH 3 cells to establish the presence of ER␤, confirm its size, and support the histological validation. Figure  3 shows a protein band of 58 -60 kDa, calculated from molecular mass markers, in all three tissues. The same electrophoretic mobility is exhibited by a recombinant human ER␤ protein. A 35-kDa band, which may be nonspecific, was also observed in some of the extracts.
Overexpression of ER␤ enhances estrogen-induced PRL gene expression in GH 3 cells
We next investigated the effects of ER␤ overexpression on estrogen induction of the PRL gene. For that, GH 3 cells were cotransfected with ER␤ expression vector, PRL promoter/luc reporter gene, and a ␤-galactosidase vector for monitoring the transfection efficiency. Western blotting confirmed that ER␤ was translated in the transfected cells (data not shown). As shown in Fig. 4 , left panel, 18 h of estradiol treatment of cells transfected with an empty vector increased PRL gene expression 3-fold over the control level. When increasing amounts of ER␤ were introduced into the cells, PRL gene expression was enhanced in a dose-dependent manner, reaching 6-fold above the control level with 25 ng ER␤ (P Ͻ 0.05). On the other hand, overexpression of ER␤, at the highest amount tested, only slightly activated a triple vitellogenin ERE (Fig. 4, right panel) .
Expression of TERP protein in GH 3 cells
We (12) and others (17) have detected a 20-kDa TERP protein in pituitary extracts. To determine whether GH 3 cells express the TERP protein, we performed Western blots. Whereas both full-length ER␣ (66-kDa) and TERP proteins were detected in the pituitary, only ER␣ was found in untreated GH 3 cells (Fig. 5) . A very weak 20-kDa protein band (evident only after overexposure of the blot) was seen in GH 3 cells incubated with 1 nm estradiol for 24 h. To examine whether GH 3 cells can translate an exogenous TERP, the cells were transfected with a TERP expression vector (gift from Dr. Friend) (24) . As shown in Fig. 5 , the transfected cells showed three protein bands, the wild-type ER␣, a 55-kDa protein of an unknown identity, and a 24-kDa protein, presumably the transfected TERP.
The pituitary uses methionine 426 as the start site for TERP translation
The difference in size between the endogenous TERP in the pituitary (20 kDa) and that expressed in transfected GH 3 cells (24 kDa; see Fig. 5 ) led us to consider alternative translation initiation sites of TERP. The exon 5 sequence contains three putative Met start sites: 393, 401, and 426 (Fig. 6) . When the original TERP expression vector, which uses Met 393 , was transfected into COS-1 cells, the resulting 24-kDa protein was larger than the endogenous pituitary TERP (Fig. 6) ; the same size protein was also seen in transfected GH 3 cells (Fig. 5) . The cDNAs with the two other potential start sites were PCR cloned and expressed in COS-1 cells. As evident, the Met 426 is probably used by the pituitary as the initiation site for TERP translation. This vector, which also produces a 20-kDa protein in GH 3 cells (data not shown), was used for further experiments.
TERP overexpression does not alter the expression of selected reporter genes
GH 3 cells were cotransfected with the TERP vector and PRL/luc or ERE/luc reporter genes, using the same paradigm as that described for ER␤. Figure 7 , left panel, shows that the TERP vector, at all concentrations examined, did not alter the estrogen-induced PRL gene expression above that obtained with an empty vector. Similarly, ERE reporter activity was unchanged by TERP overexpression (right panel). Further increases in the amount of TERP expression vector resulted in a marked decrease in the transfection efficiency, presumably because of a lower cell survival. 
Discussion
We are reporting that GH 3 cells express mRNAs for ER␣, TERP, and ER␤. Estrogen induces the expression of both ER␤ and TERP, but not ER␣, in these cells. Our novel ER␤ antibody identifies a significant number of immunopositive cells in all three lobes of the pituitary and detects a 58-kDa protein band in both the pituitary and GH 3 cell extracts. Overexpression of ER␤ significantly enhances estrogen-induced PRL gene expression, but is less effective in activating an ERE construct. On the other hand, overexpression of TERP does not alter either PRL or ERE in response to estrogen.
Both TERP and ER␤ mRNA levels in GH 3 cells were upregulated by exogenous estrogen in a time-and dose-dependent manner. The increase in TERP was biphasic, suggesting that the rapid 5-fold rise was due to a direct transcriptional effect of estrogen, whereas the delayed increase may represent a secondary effect by induced proteins. The delayed increase in the ER␤ mRNA levels appears to be due to a secondary response. In our previous in vivo study, estrogen induced an increase in anterior pituitary TERP mRNA levels, but did not alter ER␤ (12) . As the pituitary contains different estrogen-responsive cells, including lactotrophs, gonadotrophs, and folliculo-stellate cells (5, 25, 26) , specific changes in each cell type cannot be distinguished using the whole pituitary. In fact, we have estimated that only 30% of the pituitary lactotrophs express ER␤ mRNA (12) . The up-regulation of ER␤ gene expression by estrogen in GH 3 cells suggests that ER␤ in lactotrophs is sensitive to estrogen.
To examine ER␤ at the protein level, we generated polyclonal antibodies and used both immunohistochemistry and Western blotting for their characterization. Strong nuclear staining was seen in ovarian granulosa cells, as expected from in situ hybridization studies (9, 12, 27) , with the staining specificity confirmed using preabsorbed antisera. Cells with nuclear staining for ER␤ were also observed in all lobes of the pituitary, in agreement with the distribution of ER␤ mRNA- expressing cells in the pituitary (12) . Furthermore, the antibody detected a 58-to 60-kDa ER␤ protein in ovary, pituitary, and GH 3 cells. Although this protein differs slightly from the 54 kDa predicted size of the original cDNA clone (9), several ER␤ isoforms have been reported (28, 29) .
After demonstrating that GH 3 cells express ER␤, we examined whether it mediates the actions of estrogen on the PRL gene. After estrogen binds to its receptor (either ER␣ or ER␤), the receptor dimerizes and binds to an ERE consensus sequence in the promoter region of responsive genes. An imperfect palindromic ERE is located in the distal promoter region of the PRL gene, adjacent to a pit-1 site. Pit-1, a pituitary-specific transcription factor, is mandatory for estrogen induction of the PRL promoter (30, 31) . Hence, a cell line such as GH 3 with an endogenous pit-1 is an appropriate model for studying the effect of estrogen on the PRL gene.
The cotransfection experiments were designed to overexpress ER␤ and examine its action on both the PRL promoter and the vitellogenin ERE. As shown in Fig. 4 , transfection with increasing amounts of ER␤ resulted in a dose-dependent rise in estrogen-induced PRL gene expression, with a lesser activation of the ERE. A synergism between the activated receptor and pit-1 may explain the higher responsiveness of the PRL gene to estrogen than the transfected ERE. These experiments could not discriminate between homodimerization of ER␤ or its heterodimerization with ER␣, as was recently reported in vitro (10) . Experiments are underway to dissect out the roles of ER␣ and ER␤ by selectively reducing the expression of each receptor. Unfortunately, the role of ER␤ in pituitary physiology cannot be studied using the ER␣-deficient mouse (32) , because the mouse pituitary does not express ER␤ (14) (our unpublished observations).
Among the many ER␣ variants identified at the mRNA level (33) , TERP appears to be the only variant shown to be translated. Therefore, it was of interest to examine the functions that might be mediated by this truncated receptor. In the process of preparing a TERP expression vector, we identified Met 426 as the likely pituitary translation start site, based on its size similarity to the endogenous TERP protein. This methionine is flanked by the consensus initiation sequence, A/GNNATGG (34) . As TERP can bind estrogen and contains the domains for coactivator and receptor dimerization, it could suppress estrogenic action by squelching either exogenous estrogen or the wild-type receptor, or it may enhance transcription by recruiting receptor coactivators (35) . In human 293 kidney cells, transfected TERP was reported to increase ER␣-mediated activation of a vitellogenin ERE (24) . An N-terminal-truncated progesterone receptor was also shown to enhance transcription from a mouse mammary tumor virus promoter (36) . However, we were unable to demonstrate an effect of TERP overexpression in GH 3 cells on either PRL or ERE. Whereas endogenous TERP protein is detectable in the pituitary (12, 17) , only a very weak expression is evident in estrogen-treated GH 3 cells. Clearly, additional studies are needed to elucidate the role, if any, of TERP in pituitary function.
In summary, we have established that GH 3 cells, representing the pituitary lactotrophs, express ER␣, ER␤, and TERP. The precise role of each of these receptors and whether they have distinct, overlapping, or synergistic functions remain to be determined. In addition to PRL, the lactotrophs have other estrogen-regulatable genes, and it would be important to identify which receptor mediates their regulation.
